Table of Contents
ORLANDO, Fla. — AllianceRx Walgreens Prime has announced additional medicines available to patients with certain rare, chronic and complex conditions.
Known as limited distribution drugs (LDDs), these specialty medicines treat certain types of multiple sclerosis (MS), Lambert-Eaton myasthenic syndrome (LEMS) and a form of non-Hodgkin’s lymphoma (NHL), among other complex conditions. Since last spring, the following drugs have been added to the company’s list of LDDs:
• Eticovo (etanercept-ykro) is a biosimilar manufactured by Samsung Bioepis.
• Mavenclad (cladribine) tablets are manufactured by EMD Serono.
• Mayzent (siponimod) is made by Novartis.
• Polivy (polatuzumab vedotin-piiq) is manufactured by Genentech.
• Relizorb (immobilized lipase) is a digestive enzyme cartridge manufactured by Alcresta.
• Ruzurgi (amifampridine) is manufactured by Jacobus Pharmaceutical Co.
• Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) are both produced by Pfizer Inc.
“Manufacturers choose AllianceRx Walgreens Prime as a limited distribution drug partner because they value our ability to support patients throughout their treatment journey,” said Tracey James, vice president of pharmacy services at AllianceRx Walgreens Prime. “They know we are committed to delivering the high-touch care these patients need, while striving to contain costs and drive health outcomes.”
